Dominic J Gessler

List of Publications by Year
in descending order

21	473	933447 10	1125743 13
papers	citations	h-index	g-index

21	21	21	775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10. Molecular Therapy, 2014, 22, 1299-1309.	8.2	179
2	Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease. JCI Insight, 2017, 2, e90807.	5.0	49
3	A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Molecular Therapy - Methods and Clinical Development, 2018, 9, 234-246.	4.1	42
4	Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nature Biotechnology, 2018, 36, 839-842.	17.5	36
5	GammaTile^{Â®}: Surgically targeted radiation therapy for glioblastomas. Future Oncology, 2020, 16, 2445-2455.	2.4	33
6	Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties. Nature Communications, 2020, 11, 3279.	12.8	30
7	Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs. Molecular Therapy - Nucleic Acids, 2018, 10, 349-360.	5.1	24
8	Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders. Methods in Molecular Biology, 2016, 1382, 429-465.	0.9	20
9	Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System. Methods in Molecular Biology, 2019, 1950, 143-163.	0.9	20
10	Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Scientific Reports, 2017, 7, 40336.	3.3	18
11	Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair. Frontiers in Cellular Neuroscience, 2021, 15, 661928.	3.7	11
12	GammaTileÂ® brachytherapy in the treatment of recurrent glioblastomas. Neuro-Oncology Advances, 2022, 4, vdab185.	0.7	10
13	58. Pushing the Limits for Canavan Gene Therapy into Adulthood: Is There an Age Limit for Gene Therapy in CNS Disorders?. Molecular Therapy, 2016, 24, S25-S26.	8.2	1
14	586. Development of Anti-Angiogenic miRNA Therapeutics for Corneal Neovascularization. Molecular Therapy, 2015, 23, S233.	8.2	0
15	496. From Gene Therapy to Gene Enhancement: Optimized Pre-Clinical Gene Therapy Transforms Mice with the Severest Canavan Disease Phenotype Into â€œSupermiceâ€• Molecular Therapy, 2015, 23, S198.	8.2	0
16	733. Somatically Repairing Compound Heterozygous Recessive Mutations by Chromosomal Cut-and-Paste for In Vivo Gene Therapy. Molecular Therapy, 2016, 24, S289.	8.2	0
17	157. High-Field In Vivo Neuroimaging to Determine CNS Gene Therapy Outcome and Probe Disease Pathomechanism. Molecular Therapy, 2016, 24, S61-S62.	8.2	0
18	349. The Cure of Canavan Disease: Is It a Scientific Fiction or Clinical Reality?. Molecular Therapy, 2016, 24, S140.	8.2	0

#	Article	IF	Citations
19	351. Efficacious Non-Oligodendrocyte Gene Therapy Suggests a New Dogma About CNS Compartmentalization of NAA Metabolism and Supports a Metabolic Sink Theory. Molecular Therapy, 2016, 24, S140-S141.	8.2	0
20	366. Hitting Two Birds with One Stone: How Efficacious Pre-Clinical Gene Therapy Cures Canavan Disease and Sheds Light onto the Pathomechanism. Molecular Therapy, 2016, 24, S147.	8.2	0
21	739. rAAV Delivered MicroRNA Therapeutics Towards Efficacious Treatment of Corneal Neovascularization. Molecular Therapy, 2016, 24, S291.	8.2	0